Madrigal Pharmaceuticals To Present Multiple Rezdiffra Abstracts In NASH/MASH At The AASLD Liver Meeting
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals will present multiple abstracts on their drug resmetirom for NASH/MASH at the AASLD Liver Meeting in November 2024.
October 30, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals is set to present multiple abstracts on resmetirom, a drug for NASH/MASH, at the AASLD Liver Meeting in November 2024.
The presentation of multiple abstracts on resmetirom at a major liver disease conference could generate positive attention and investor interest, potentially boosting MDGL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100